MED Therapy Pro

improves the tolerance of chemotherapy¹

Clinical study on the reduction of chemotherapy-induced side effects through treatment with PMA zeolite¹

Study Design:

randomized, double-blind, placebo controlled

Inclusion Criteria:

histologically confirmed cancer diagnosis, ≥ 18 years of age predominantly colorectal carcinoma

Duration: 3.5 years

Number of Patients: 120 adults (thereof 112 Colon carcinoma)

Dosage:

3 g PMA zeolite orally 2 times a day or placebo during and until 1 month after completion of chemotherapy: Oxaliplatin derivatives (highly neurotoxic, adjuvant / first line / second line)

Method & Diagnostics:

Measurement of nerve conduction velocity (NCS): Before initiation, after 3 and 6 months; chemotherapy-induced peripheral neuropathy (CIPN), hematologic toxicity, during the chemotherapy cycle Scientific Lead:

**

Prof. G. Carteni, Dr. med. M. G. Vitale

Molecules, Open Access Journal by MDPI, listed in PubMed, Cite-Score: 3.28 (Scopus), Impact Factor: 3,060

Clinical study results¹:

- **Compliance: 21 % less therapy cancellations** (p = 0,03)* thanks to PMA zeolite treatment
- Hematologic toxicity: 72 % lower incidence of severe toxicity (G2-G3) in the PMA zeolite group (p = 0.09)**
- CIPN: Significant reduction of CIPN (Chemotherapy Induced Peripheral Neuropathy) by 28 % in the subgroup of men $(p = 0.047)^{***}$

First results of the follow-up data²:

- **PFS: Positive trend for PFS** for elderly patients > 70 years of age (p = 0.1)****
- OS: In terms of overall survival rate in 1st line patients showed an advantage for the PMA zeolite group, with 29 % lower mortality (p = 0.1)*****

patients with more than eight chemotherapy cycles trend to severe toxicity (G2-3) in the placebo-group compared to the PMA zeolite-group (12.1 % vs. 3.4 %)

**** there is neither a trend nor significance with women (p=0.43) **** PFS = Progression Free Survival ***** OS = Overall Survival

PANACEO MED THERAPY-PRO


enables better adherence to the oncology treatment protocol



improves the tolerance of

chemotherapy¹

71.7 % of the patients receiving cancer therapy were able to complete eight chemotherapy cycles thanks to the additional PMA zeolite treatment (p = 0.03)



Your **active** companion!



THERAPY